1. Generics Bulletin
  2. >>Business

Sanofi’s Generics Sales Stabilize Post-Zentiva

Emerging Markets Now Account For The Bulk Of Generics Turnover

 
• By Akriti Seth

Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.

Emerging_Markets
Emerging markets now account for the bulk of Sanofi’s generics sales • Source: Shutterstock

Sanofi’s generics sales decreased by just 0.4% at constant exchange rates and grew by 0.4% as reported to €271m ($296m) in the fourth quarter of 2019, representing the first quarter in which the prior-year comparison did not include the Zentiva generics business in Europe.

Zentiva was divested to private-equity firm Advent International at the end of the third quarter of 2018. (Also see "Zentiva sets strategy as it starts out alone" - Generics Bulletin, 5 October, 2018

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.